No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Operating as a specialized pharmaceutical company, Ajanta Pharma Limited, together with its subsidiaries, is involved in the entire lifecycle of finished drug formulations, from their development and manufacturing to market distribution. Its comprehensive portfolio caters to diverse therapeutic segments, including treatments for malaria, cardiovascular conditions, eye care, skin disorders, pain, digestive health, allergies, respiratory illnesses, and diabetes. The company produces a wide array of pharmaceutical forms, such as tablets, capsules, powders, liquids, jellies, ointments, sterile eye drops, and also active pharmaceutical ingredients (APIs). Ajanta Pharma's market presence spans India, numerous African nations, other parts of Asia, the United States, and extends internationally. Established in 1973, its headquarters are situated in Mumbai, India.
www.ajantapharma.comNo one on the platform currently holds AJANTPHARM.BO.
No tracked institution reports a position in AJANTPHARM.BO as of their last filing.
No one on the platform has traded AJANTPHARM.BO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 21.7% | 21.1% | 22.1% | — | — | — |
| Rev. Growth % | 18.9% | 13.9% | ||||
| Profit Margin % | 19.4% | 19.3% | 20.6% | |||
| Free Cash Flow Margin % | 2.8% | 13.1% | 10.7% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $62.9B | +17.2% | $100.22 | $94.17–$103.75 | — | 12 |
| 2028 | $70.7B | +12.5% | $115.81 | $103.31–$123.44 | — | 13 |
| 2029 | $79.8B | +12.8% | $130.65 | $113.27–$143.04 | — | 5 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 6 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-30 | $23.04 | $26.72 | +16.0% |
| 2026-05-05 | $20.13 | $21.30 | +5.8% |
| 2026-01-30 | $19.83 | $21.91 | +10.5% |
| 2025-10-27 | $20.54 | $20.80 | +1.3% |
| 2025-07-27 | $19.65 | $20.43 | +4.0% |
| 2025-05-02 | $19.70 | $18.00 | -8.6% |
| 2025-01-29 | $17.50 | $18.59 | +6.2% |
| 2024-10-27 | $17.70 | $17.26 | -2.5% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| AJANTPHARM.BOAjanta Pharma Limited | $3506.25 | -0.87% | $437.4B | — |
| COHANCE.BOCohance Lifesciences Limited | $423.60 | -4.07% | $161.7B | — |
| COHANCE.NSCohance Lifesciences Limited | $423.60 | -3.77% | $162.1B | — |
| GLAND.BOGland Pharma Limited | $2880.45 | -1.69% | $474.9B | — |
| GLAND.NSGland Pharma Limited |
| $2895.50 |
| -0.92% |
| $477.6B |
| — |
| IPCALAB.BOIpca Laboratories Limited | $1934.30 | -1.66% | $494.4B | — |
| IPCALAB.NSIpca Laboratories Limited | $1938.90 | -1.50% | $491.9B | — |
Source: Financial Modeling Prep · peers by sector/industry